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Marek Kielbinski & Dariusz Woszczyk & Stanisław Potoczek & Anna Jonkisz &
Kazimierz Kuliczkowski & Irena Frydecka
Abstract V arious phenotype and functional T-cell abnor-
malities are observed in multiple myeloma (MM) patients.
The aim of this study was to investigate the association
between polymorphisms in the gene encoding cytotoxic T-
lymphocyte antigen-4 (CTLA-4), a negative regulator of
the T-lymphocyte immune response and susceptibility to
multiple myeloma in a Polish population. Two hundred
MM patients and 380 healthy subjects were genotyped for
the following polymorphisms: CTLA-4c.49A>G, CTLA-
4g.319C>T, CTLA-4g.*642A T(8_33), CT60 (CTLA-4g.
*6230G>A), Jo31 (CTLA-4g.*10223G>T). Our study is
the largest and most comprehensive evaluation to date of
the association between genetic polymorphisms in the
CTLA-4 molecule and multiple myeloma. It was found
that CTLA-4c.49A>G[G], CT60[G], and Jo31[G] alleles
were more frequently observed in MM patients than in
controls (0.50 vs. 0.44, p=0.03, 0.65 vs. 0.58, p=0.04,
a n d0 . 6 3v s .0 . 5 7 ,p=0.03, respectively). Moreover, the
haplotype CTLA-4c.49A>G[G], CTLA-4g.319C>T[C],
CTLA-4g.*642A T(8_33) [8], CT60[G], Jo31[G] including
all susceptibility alleles increases the risk of MM about
fourfold (OR: 3.79, 95%CI: 2.08–6.89, p=0.00001).
These findings indicate that genetic variations in the
CTLA-4 gene play role in susceptibility to multiple
myeloma and warrant further investigation through repli-
cation studies.
Keywords CTLA-4.Gene polymorphisms.MM
Introduction
Multiple myeloma (MM) is a B-cell neoplasm characterized
by the proliferation and accumulation of isotype-switched
immunoglobulin-producing monoclonal plasma cells in the
bone marrow and by overproduction of monoclonal
immunoglobulins that can be detected in serum and/or
urine. Previous studies reported that MM patients may
exhibit a variety of T-cell abnormalities, such as a marked
reduction in the proportions of CD4 and CD8 cells
expressing co-stimulatory molecules, signal transduction
components, and Th1/Th2 imbalance, particularly in ad-
vanced stages of MM [1–5]. The involvement of altered T-
cell response in the development of murine plasmacytomas
has also been reported [6]. The effective activation of naïve
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antigen-specific signal, is sent via a unique antigen
receptor, the T-cell receptor (TCR), on T-cells. The second
signal, termed co-stimulation, is critical for allowing full
activation, sustaining cell proliferation, preventing anergy
and/or apoptosis, inducing differentiation to effector and
memory status, and allowing cell-cell cooperation. CD28
is the primary T-cell co-stimulatory molecule and is
constitutively expressed on the majority of T-cells.
Cytotoxic T-cell antigen (CTLA-4) is a homologous
molecule of CD28 which plays an inhibitory role in the
early and late stages of T-cell activation [7]. CTLA-4
ligation provides a negative signal for regulation of the cell
cycle and inhibits the activity of the transcriptional factors:
nuclear factor-κΒ (NF-κΒ), nuclear factor of activated T-
cells (NF-A T), and activator protein 1 (AP-1). Moreover,
CTLA-4 binds to CD28 ligands (CD80 and CD86) with
higher affinity and avidity and in that way also inhibits T-
cell activation [8].
Several reports have indicated that CTLA-4 gene poly-
morphisms are implicated in malignancies [9–14]. To the
best of our knowledge, no large cohort-based study on gene
polymorphisms of co-stimulatory and down-regulatory
molecules has been performed in MM. Only one report
was devoted to an association between the CTLA-4g.*642A T
(8_33) polymorphism and susceptibility to MM [15].
Therefore we undertook a study to investigate the relation-
ship between CTLA-4c.49A>G (rs231775), CTLA-
4g.319C>T (rs5742909), CTLA-4g.*642A T(8_33), CTLA-
4g6230G>A (CT60, rs3087243), CTLA-4g.10223G>T
(Jo31, rs11571302) gene polymorphisms and MM incidence,
age at disease onset, ISS, M component type, light chain,
response to treatment, and time to disease progression.
The polymorphic markers we chose for our study are
reported to be functional and to be associated with altered
immune responses. The CTLA-4g.319C>T single nucleo-
tide polymorphism (SNP) influences promoter activity and
the expressions of both CTLA-4 mRNA in unstimulated
cells and cell-surface CTLA-4 on activated cells [16–19].
The A>G transition at position 49 in exon (CTLA-
4c.49A>G) causes a Thr/Ala substitution in the leader
peptide [20]. This polymorphism affects the inhibitory
function of CTLA-4 [16, 21]. The dinucleotide short repeat
polymorphism CTLA-4g.*642A T(8_33) at position 642 in
the 3′untranslated region (UTR) influences the level of
mRNA transcription [22]. The CTLA-4g.*6230G>A
(CT60) polymorphism was shown to be associated with
variations in the mRNA level of soluble CTLA-4 [24].
Results published by us indicate that the Jo31 polymor-
phism together with CT60 is associated with the levels of
membrane and cytoplasmic CTLA-4 in CD4+ T lympho-
cytes from multiple sclerosis patients [23] and with the
variation of serum soluble CTLA-4 level in Graves-Basedow
patients [24]. Moreover, all the investigated polymorphisms
are associated with susceptibility to malignancies [9, 11–14].
The results from the present study indicate that CTLA-4
gene polymorphisms are related to susceptibility to multiple
myeloma in a Polish population.
Materials and Methods
Study Population
The study enrolled 200 unrelated Polish patients with
multiple myeloma came from two centers: 148 from the
Department of Haematology, Neoplastic Diseases & Bone
Marrow Transplantation of the Medical University in
Wroclaw, and 52 from the Department of Haematology of
the State Hospital in Opole. There were 106 women and 94
men aged 33 to 85 (median±SD, 67±10.9 years), and the
median age at diagnosis was 63.5±11.2 years. The
diagnosis of multiple myeloma was based on criteria
established by the International Myeloma Working Group
[25]. Clinical stage was assessed according to the
International Staging System (ISS) for Multiple Myeloma
and was determined during enrolment in the study [26],
i.e. stage 1 with serum β2microglobulin less than 3.5 mg/l
+serumalbumin≥3.5 g/dl, stage 2 with neither stage 1 nor
3, and stage 3 with serum β2microglobulin level ≤5.5 mg/
l. The patients were treated according to the melphalan+
prednisone (MP); vincristine, doxorubicin (Adriamycin),
dexamethasone (V AD); vincristine, melphalan, cyclophos-
phamide, prednisone (VMCP); or cyclophosphamide,
thalidomide, dexamethasone (CTD) protocol. Table 1
summarizes the clinical characteristics of the MM patients.
The control group included 380 healthy Polish individ-
uals originating from the same geographical area as the
patients (214 female and 166 male) with the majority
recruited from the blood bank in Wroclaw and others
recruited among employees of the Institute of Immunology
and Experimental Therapy. Genetic homogenity of the
Polish population is observed, as reflected in virtually
identical frequencies of H-Y polymorphisms in different
regions of Poland [27]. All enrolled participants were
informed about the study protocols and consent was
obtained from each individual. Data on participation rate
were not available. The study was approved by the local
ethics committee.
Genotyping/Determination of Polymorphisms
A single nucleotide polymorphisms (SNPs) g.319C>T in
the promoter region, c.49A>G in exon 1, and CT60 in the
3′UTR of the CTLA-4 gene were examined by polymerase
chain reaction–restriction fragment length polymorphism
220 L. Karabon et al.(PCR-RFLP) using TruI, BseXI, and TailI enzymes (Fer-
mentas, Burlington Ontario, Canada). Table 2 lists the
conditions of PCR product digestion with the restriction
enzymes. Table 3 lists the primer sequences for PCR. The
PCR reaction was carried out as described previously.
The Jo31 CTLA-4 gene polymorphism was genotyped by
the allelic discrimination method on the Applied Biosystems
7300 Real-Time PCR System using the TaqMan SNP
Genotyping Assay-on -Demand (Applied Biosystems, War-
rington, UK).
The CTLA-4 3′ UTR containing (A T)n repeats was
amplified with a pair of primers (listed in Table 3) in which
the 5′ ends of the forward primers were labelled with JOE
and 6-FAM, respectively (Bionovo, Legnica, Poland). The
detailed procedure is described in Suwalska et al. [9].
For quality controls we performed 5% to 10% re-typing
with double blind check. For all SNPs additionally typing
with other genotyping methods was used. Re-typing
methods were as follows: g.319C>T SNP in the promoter
region, c.49A>G in exon 1, and CT60 in the 3′ UTR of the
CTLA-4 gene were genotyped using PCR and then single-
nucleotide primer-extension methods as described in
Suwalska et al. [9], while the Jo31 SNP was genotyped
using PCR and then single-nucleotide primer-extension
methods as described in Karabon et al. [23].
The primers were designed according to the complete
CTLA-4 gene sequence derived from the NCBI Sequence
Viewer.
Statistical Analyses
The evaluation of Hardy-Weinberg equilibrium was per-
formed independently for the patients and control group by
comparing the observed and expected frequencies of geno-
types using χ
2 analysis. The χ
2 test was used to compare
categorical data between patients with MM and controls.
Odds ratios (OR) and 95% confidence intervals (95%CI)
were calculated using the binary logistics regression model.
The linkage disequilibrium (LD) coefficients D′=D/Dmax
and r
2 for the pair of the most common alleles at each locus
and haplotype frequencies for pairs of alleles were deter-
mined using the SHEsis program (http://202.120.7.14/
analysis/myAnalysis.php)[ 28]. Haplotypes with frequencies
lower than 0.03 were not considered.
Results
CTLA-4 Polymorphisms and Susceptibility to MM
The distributions of the alleles and genotypes of all studied
polymorphisms in the MM patients and the healthy control
group are shown in Table 4. Neither in cases nor in controls
was deviation from Hardy-Weinberg equilibrium observed
Table 1 Patients’ characteristics
Number of patients 200
Age (median, st.
dev., range)
67±10.7
(33–87)
Age of onset
(median, st.
dev., range)
63.5±11.2
(32–84)
Gender
(female/male)
106/94
International
Staging System
(ISS)
17 3
26 6
36 1
Ig subtype IgG 115
IgA 45
IgM 5
IgD 1
Non-secretory 4
Light chain 13
others 17
Light chain type κ 67%
λ 33%
Number of controls 380
volunteers of blood bank 329
employee of Institute of
Immunology& Experimental
Therapy
51
Gender of controls (female/male) 214/166
Table 2 Conditions for PCR product digestion with restriction enzymes
Amplicon [bp] SNP Enzyme Temperature and duration of digestion Digestion products visible on gel [bp]
814 CTLA-4g.319C>T TruI 65°C, 3 h C: 51, 101, 100, 562
T: 51, 101, 100, 94, 468
814 CTLA-4c.49A>G BseXI 65°C, 4 h A: 207, 607
G: 207, 508, 99
806 CT60 TailI 65°C, 4 h G: 419, 236, 151
A: 236, 570
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intervals (CI) in Table 4 are shown for the codominant
model. For the microsatellite polymorphism CTLA-4g.
*642A T(8_33) the alleles were grouped arbitrarily into two
groups, i.e. short ([8] 8 repeats) and long ([>8], >8 repeats)
alleles.
The exon 1 CTLA-4 gene polymorphism at position +49
was found to be associated with MM. The frequency of the
CTLA-4c.49A>G[G] allele was significantly higher in the
MM patients than in the controls (p=0.03),withanestimated
odds ratio (OR) of 1.31 and a 95% confidence interval (CI)
of 1.03–1.68. Moreover, the distributions of the genotypes
were different in the patients and controls. Individuals
possessing [G] alleles (genotypes [GG] and [AG]) were
present significantly more frequently among patients than
controls (p=0.02, OR: 1.61, 95%CI: 1.08–2.44).
Moreover, the Jo31 SNP contributed to the risk of MM.
The Jo31 [G] allele and [GG] genotype were associated with
increased the risk of MM (OR: 1.32, p=0.03, 95%CI: 1.03–
1.69 and OR: 1.46, p=0.04, 95%CI: 1.02–2.08, respectively)
(Table 4).
Additionally we noted a significantly higher frequency
of the CT60 [G] allele and a trend toward over-expressing
the [GG] genotype in MM patients compared with controls
(p=0.04, OR: 1.3, 95%CI: 1.11–1.68 and p=0.07, OR:
1.41, 95%CI: 0.97–1.99, respectively) (Table 4).
The distribution of alleles and genotypes in CTLA-
4g.319C>T and CTLA-4g.*642A T(8_33), polymorphisms
did not differ between the group of MM patients and controls.
The global distributions of the haplotypes differed
significantly between the cases and controls (pafter Bonferroni
correction=7.5e-005) (Table 5). The haplotype CTLA-
4c.49A>G[G]/CTLA-4g.319C>T[C]/CTLA-4g.*642A T
(8_33)[8]/CT60[G]/Jo31[G] was overrepresented in the
cases compared with the controls (OR: 3.79, 95%CI: 2.08–
6.89, p=0.00001).
CTLA-4 Gene Polymorphisms and Clinical Data
in Multiple Myeloma Patients
Because multiple myeloma occurs more frequently in males
than in females, we conducted a separate association test of
all the studied polymorphic markers, i.e., CTLA-4c.49A>G,
CTLA-4g.319C>T, CTLA-4g.*642A T(8_33), CT60, and
Jo31 in the CTLA-4 gene in male and female participants.
We noted an even stronger association between the CTLA-
4c.49A>G[G] allele and susceptibility to MM in males
(OR:1.61, 95%CI:1.11–2.33, p=0.01). None of the studied
polymorphic markers correlated with the clinical data
regarding: age at disease onset, ISS, M component type, light
chain, response to treatment, or time to disease progression.
Linkage Disequilibrium
The investigated polymorphisms in the 3′ UTR, namely,
Jo31, CT60, and CTLA-4g.*642A T(8_33) were in strong
linkage disequilibrium with each other expressed by either
D′ or r
2 (Table 6). In the case of pairs CTLA-4c.49A>G and
CTLA-4g.319C>T; CTLA-4c.49A>G and CTLA-4g.*642A T
(8_33); CTLA-4g.319C>T and CTLA-4g.*642A T(8_33);
CTLA-4c.49A>G and CT60; CTLA-4c.49A>G and Jo31;
CTLA-4g.319C>T and CT60; and CTLA-4g.319C>T and
Jo31 linkage disequilibrium between them was expressed
by D′ (Table 6).
Discussion
Both genetic and environmental factors have been associated
with an increased risk of MM.
Family history of MM in a first-degree relative suggested
that genetic variation plays a role in the etiology of multiple
myeloma [29]. The genetic susceptibility to multiple
myeloma has not been extensively studied, although some
studies have evaluated polymorphisms in immune response
genes especially cytokine [30–32]. Others were devoted to
variations in genes involved in xenobiotics metabolism [33],
DNA repair [34], the cell cycle and apoptosis [35].
Genes encoding proteins involved in T-cell activation
and suppression have been considered as candidate genes
for many autoimmune [36–38] and, recently, also for
neoplastic diseases [9, 13, 14]. Only one study was devoted
to the association of one polymorphic marker of the CTLA-
4 gene and multiple myeloma [15].
Table 3 Primer sequences and annealing temperatures used for CD28, CTLA-4, and ICOS genotyping.
Polymorphic site Type of reaction Primer sequence Product size [bp] Tm [°C]
CTLA-4c.49A>G (rs231775) PCR F: 5′– TCT TTT CCg CCTA TT TTC AgT T− 3′ 814 58
CTLA-4g.319C>T (rs5742909) R: 5′–CAC CTC CTC CA T CTT CA T gCT CC − 3′
CT60 (rs3087243) PCR F: 5′–Tgg gCC CAATTC TTA CAA AC − 3′ 806 58
R: 5′–CAg gA T gTg gAg gTC AAA AA− 3′
CTLA-4g.*642A T(8_33) PCR F: (JOE) 5′–gCC AgT gA T gCTAAA ggT Tg−3′ 82–132 52
R: 5′–TgC CAg TTC CCTACA AgA Ag−3′
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CTLA-4 gene, three of them (CTLA-4c.49A>G, CT60, and
Jo31) were significantly associated with MM. We observed
that CTLA-4c.49A>G[G] allele, the Jo31[G] allele and
[GG] genotype and the CT60[G] allele increased the risk of
developing MM.
It is of great interest that genetic variants of the studied
polymorphisms have been previously reported to contribute
to a lower expression level of mRNA and/or CTLA-4
molecule expression on T-cells [16, 21, 23, 39]. CTLA-
4c.49A>G transition is a functional polymorphism which
influences T-cell activation and therefore might play a role
in altered T-cell regulation. Presence of [GG] genotype was
shown to be associated with significantly higher activation
of T lymphocytes and higher proliferation than [AA]
genotype. The protein product coded by CTLA-4c.49A>G
[GG] genotype CTLA-4
17Ala had lower capacity to bind
B7.1 and a weaker inhibitory effect on T-cell activation
compared with CTLA-4
17Thr [40]. It has also been
postulated that the CTLA-4c.49A>G polymorphism in the
leader sequence may influence rates of endocytosis or
surface trafficking [21], the glycosylation of CTLA-4, and
Table 4 CTLA-4c.49A>G, CTLA-4g.319C>T, CTLA-4g.*642AT(8_32), CT60G>A, genotypes and alleles frequencies in MM patients and
controls
Multiple myeloma n=200 Controls group n=380 p OR 95%CI Global p
CTLA-4c.49A>G Allele A 199 (50.0%) 417 (56.3%) 0.03 0.77 0.60–0.97
G 199 (50.0%) 318 (43.7%) 1.31 1.03–1.68
Genotype A/A 48 (24.1%) 124 (33.4%) reference
A/G 103 (51.8%) 169 (45.6%) 0.03 1.57 1.04–2.38 0.07
G/G 48 (24.1%) 75 (21.0%) 0.04 1.65 1.01–1.86
Carriers of G+ 151 (76.9%) 244 (66.6%) 0.02 1.61 1.08–2.44
G- 48 (24.1%) 124 (33.4%) 0.63 0.41–0.93
CTLA-4g.319C>T Allele C 356 (89.4%) 672 (90.2%) 0.64 0.90 0.61–1.36
T 42 (10.6%) 72 (9.8%) 1.10 0.73–1.64
Genotype CC 155 (79.5%) 297 (80.9%) reference
CT 40 (20.5%) 68 (18.5%) 0.59 1.13 0.73–1.74 0.43
TT 0 (0.0%) 2 (0.6%) 0.86 ––
Carriers of T+ 40 (20.5%) 70 (19.1%) 0.68 1.09 0.71–1.698
T- 155 (79.5%) 297 (80.9%) 0.91 0.59–1.41
CTLA-4g.*642AT(8_32) Allele 8 190 (47.5%) 350 (46.1%) 0.64 1.06 0.83–1.35
>8 210 (52.5%) 410 (53.9%) 0.94 0.74–1.20
Genotype 8/8 55 (27.5%) 94 (24.7%) reference
8/>8 80 (40.0%) 162 (42.6%) 0.43 0.84 0.55–1.82 0.74
>8/>8 65 (32.5%) 124 (32.6%) 0.63 0.89 0.57–1.40
Carriers of 8+ 135 (67.5%) 256 (68.4%) 0.97 1.00 0.70–1.45
8− 65 (32.5%) 124 (32.6%) 0.99 0.69–1.43
CT60G>A Allele G 249 (64.5%) 444 (58.4%) 0.04 1.30 1.11–1.68
A 137 (35.5%) 316 (41.76%) 0.77 0.60–0.90
Genotype G G 81 (41.7%) 128 (34.2%) reference
G A 88 (45.8%) 180 (48.1%) 0.18 0.93 0.64–1.28 0.14
A A 24 (12.5%) 66 (17.6%) 0.04 0.57 0.33–99
Carriers of A+ 112 (58.3%) 246 (65.8%) 0.07 0.71 0.50–1.03
A- 81 (41.7%) 128 (34.2%) 1.40 0.97–1.99
Jo31G>T Allele G 253 (63.2%) 425 (56.5%) 0.03 1.32 1.03–1.69
T 147 (36.8%) 327 (43.5%) 0.76 0.59–0.97
Genotype G G 80 (40.0%) 118 (31.4%) reference
G T 93 (46.5%) 189 (50.3%) 0.39 0.86 0.61–1.21 0.08
T T 27 (13.5%) 69 (18.4%) 0.14 0.69 0.43–1.23
Carriers of A+ 120 (60.0%) 258 (68.6%) 0.04 0.68 0.48–0.98
A- 80 (40.0%) 118 (31.4%) 1.46 1.02–2.08
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inhibitory function of that molecule [16]. Our previous
results indicated that presence of G alleles in polymorphic
sites CT60 and Jo31 was associated with the lower levels of
membrane and cytoplasmic CTLA-4 in CD4+ T lympho-
cytes from multiple sclerosis patients [23] and with the
variation of the serum soluble CTLA-4 level in Graves-
Graves’ disease patients [24].
In fact a marked reduction, particular in advanced stage
of MM, in the proportion of CD4 and CD8 cells expressing
CTLA-4, CD28, CD3zeta, p56lck, ZAP-70 and PI3-k,
what indicate that profound and multiple T-cell signalling
defects, from the surface and down-stream, consistent with
involvement of a master T-cell function, especially in
advanced stage MM [1].
In the only report about an association of CTLA-4 gene
polymorphism and MM published previously by Zheng et
al. [15], the prevalence of longer CTLA-4g.*642A T(8_33)
alleles, which are associated with lower stability of mRNA
for CTLA-4 was described. In our study we also observed
nonsignificantly increased frequency of longer alleles.
Our findings regarding CTLA-4 gene polymorphisms
and susceptibility to MM are different from those we
obtained for B-cell chronic lymphocytic leukaemia (B-
CLL) [9], in which the CTLA-4g.319C>T[T] allele was
significantly associated with disease. Although it seems
surprising, population studies based on a positive family
history of lymphoproliferative neoplasms indicated that the
genetic pathway involved in the etiology of chronic
lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma
(NHL), and Hodgkin’s lymphoma (HL) is different from
that of MM. It was shown that first-degree relatives of
chronic CLL patients are at higher risk of developing CLL,
NHL, and HL, but not at increased risk of developing MM
[41, 42]. In contrast, first-degree relatives of MM patients
are not at risk of developing B-CLL, CLL, NHL, or HL
[17].
A limitation of this study is the relatively small group of
patients, but it should be mentioned that the population risk
of MM is approximately 0.00003 and it is difficult to
collect a bigger homogeneous ethnically matched cohort.
Therefore our findings should be confirmed by an inde-
pendent study on a larger cohort.
Our original findings of the prevalence of the CTLA-
4c.49A>G[G], Jo31[G], and CT60[G] alleles suggested that
genetic variations in the CTLA-4 gene play a role in
multiple myeloma and warrant further investigation through
replication studies.
Table 5 Haplotype estimation analysis of investigated polymorphisms within CTLA-4 gene
CTLA-4c.49A>G/ Multiple myeloma
n=200
Controls group
n=380
OR 95%CI p p after Bonferroni correction
CTLA-4g.319C>T/
CTLA-4g.*642A T (8-32)/
CT60 G>A/
Jo31 G>T
A C 8 AT 97.72 (0.28) 256.28 (0.36) 0.70 [0.53~0.94] 0.02 0.1
A C >8 G G 22.61 (0.07) 36.35 (0.05) 1.33 [0.78~2.29] 0.30
AT >8 G G 24.02 (0.07) 50.04 (0.07) 1.01 [0.61~1.68] 0.97
G C 8 AT 16.54 (0.05) 17.21 (0.03) 2.08 [1.04~4.14] 0.03 0.15
G C 8 G G 30.33 (0.09) 18.17 (0.03) 3.79 [2.08~6.89] 3.67e-006 1.0e-005
G C >8 G G 111.33 (0.32) 257.64 (0.37) 0.854 [0.64~1.13] 0.27
Global result:
Total control=700.0, total case=346.0, Global chi2 is 29.923019 while df=5, Fisher’s p value is 1.58e-005, pafter Bonferroni correction=7.5e-005
Table 6 Linkage disequilibrium analysis in CTLA-4 gene
CTLA-4c.49A>G CTLA-4g.*642A T(8_33) CT60 Jo31
D′ r
2 D′ r
2 D′ r
2 D′ r
2
CTLA-4g.319C>T 0.883 0.074 0.546 0.028 0.906 0.060 0.805 0.050
CTLA-4c.49A>G 0.567 0.237 0.769 0.320 0.770 0.353
CTLA-4g.*642A T(8_33) 0.924 0.651 0.818 0.537
CT60 0.901 0.752
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